HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-1745v1 31/2/363    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Cubbon, R. M. Articles by Hall, A. S. PubMed PubMed Citation Articles by Cubbon, R. M. Articles by Hall, A. S. Social Bookmarking                What's this?

Aspirin and Mortality in Patients With Diabetes Sustaining Acute Coronary Syndrome

¹ Leeds Institute of Genetics, Health & Therapeutics, LIGHT Laboratories, University of Leeds, Leeds, U.K
² British Heart Foundation Heart Research Centre, Jubilee Wing, Leeds General Infirmary, Leeds, U.K
³ Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Leeds, U.K

Address correspondence and reprint requests to Mark T. Kearney, Leeds Institute of Genetics, Health & Therapeutics, LIGHT Laboratories, University of Leeds, Clarendon Way, Leeds, LS2 9JT, U.K. E-mail: m.t.kearney{at}leeds.ac.uk

OBJECTIVE—We sought to compare mortality reduction associated with secondary prevention in patients with and without diabetes after acute coronary syndrome (ACS).

RESEARCH DESIGN AND METHODS—We conducted a cohort study involving 2,499 patients with ACS recruited from 11 U.K. hospitals. Multivariable analysis comparing all-cause mortality risk reduction associated with pharmacologic agents in patients with and without diabetes.

RESULTS—Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0.50–1.08); nondiabetic patients derived a 48% mortality reduction (P < 0.001). The interaction between diabetes and aspirin use was statistically significant (P = 0.037), indicating that patients with diabetes experience less effective mortality reduction from aspirin use.

CONCLUSIONS—Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with diabetes and unstable coronary artery disease.

Abbreviations: ACS, acute coronary syndrome

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. B. Hirsch, S. E. Inzucchi, and M. S. Kirkman Standards of Medical Care in Diabetes--2008: Response to Dora, Kramer, and Canani Diabetes Care, May 1, 2008; 31(5): e45 - e45. [Full Text] [PDF]